Sapart et al. suggest a combination of methotrexate and biologic disease-modifying anti-rheumatic drugs as induction therapy for patients with early RA may lead to long-term remission.
Research Outlines Benefits of bDMARDs to Treat Early RA
ACR Offers Evaluation & Management Coding Lunch & Learn Series
ACR practice management staff are offering a free, tailored, one-hour Lunch & Learn series to help members, practices and their staff become familiar with new office and outpatient evaluation and management codes and documentation guidelines that went into effect Jan. 1.
UnitedHealthcare Designates Avsola, Inflectra Preferred Infliximab Products
On Feb. 1, UnitedHealthcare enacted a new policy designating Avsola and Inflectra as the preferred infliximab products for UHC commercial plans. ACR leaders have urged UHC to allow existing patients to continue on their current medication.
Study Examines Tofacitinib’s Long-Term Cardiovascular Risk & More
In a post-marketing safety study, tofacitinib did not prove non-inferior to tumor necrosis factor inhibitors when evaluated for its long-term effects on heart disease, malignancies and serious infections in RA patients.
Rosalind Ramsey-Goldman, MD, DrPH, Becomes Next Chair of the Collaborative Initiatives Special Committee
At the helm of the Collaborative Initiatives Special Committee (COIN), Rosalind Ramsey-Goldman, MD, DrPH, will oversee projects to tackle disparities within rheumatologic care, improve the inclusiveness of ACR initiatives, advance professional development in rheumatology topics and more.
European Commission Approves Upadacitinib for Psoriatic Arthritis & Ankylosing Spondylitis
In January, upadacitinib was approved for use in Europe as a 15 mg, once-daily dose to treat patients with psoriatic arthritis and ankylosing spondylitis.
FDA Approves New Rituximab Biosimilar & Anakinra to Treat a Rare Disease
The FDA has approved anakinra to treat a rare autoinflammatory disease, deficiency of interleukin 1 receptor antagonist. The administration also approved a new rituximab biosimilar, Riabni, for multiple indications.
A High HAQ at Baseline in Early RA Is a Bad Sign
In this study, Fatima et al. analyzed how well the Health Assessment Questionnaire (HAQ) disability index predicts future all-cause mortality in patients with early RA (i.e., with a symptom duration of less than one year). A total of 1,724 patients with early RA were included. The researchers found that a higher HAQ score and Disease Activity Score at one year were significantly associated with all-cause mortality.
Late-Breaking Abstract Session Spans the Realm of Drug-Related Research
In the late-breaking abstract session at ACR Convergence 2020, drug research for a variety of indications is reviewed.
- « Previous Page
- 1
- …
- 159
- 160
- 161
- 162
- 163
- …
- 814
- Next Page »